Highest-materiality recent filing
Company held investor call on April 30, 2026 at 1:00 p.m. PT to provide corporate and clinical update.
CytoDyn extends $57M convertible notes maturity by 36 months, pays $1M/month in stock
Note 1 ($28.5M) maturity extended to April 5, 2029; Note 2 ($28.5M) to April 23, 2029.
CytoDyn raises $17.5M via private placement of 81.4M units at $0.2153 per unit
Private placement of ~81.4M units (share + warrant) to accredited investors for ~$17.5M in cash.
CytoDyn agrees to settle securities class action for $500K cash and 49M shares
Settlement in principle: $500,000 cash plus 49 million shares for dismissal of all claims.
CytoDyn shareholders approve increase in authorized shares to 2.25B; all directors reelected
Authorized common stock increased from 1.75B to 2.25B shares; approved 671,591,768 For vs 69,716,006 Against.
CytoDyn secures $30M equity funding commitment from Yorkville Advisors over 36 months
Up to $30M in common stock sales to Yorkville over 36 months; company controls timing, no minimum draws.
CytoDyn swaps auditor from Marcum to CBIZ after Marcum resignation; no accounting disagreements
Marcum LLP resigned as independent auditor effective May 14, 2025; CBIZ CPAs P.C. engaged same day for FY ending May 31, 2025.
CytoDyn appoints Robert E. Hoffman as CFO effective May 15, 2025
Hoffman replaces interim CFO Mitch Cohen; Cohen resigns effective May 12 with last day May 30.
CytoDyn shareholders elect all director nominees at 2024 Annual Meeting
Tanya Durkee Urbach, Stephen M. Simes, Ryan M. Dunlap, Lishomwa C. Ndhlovu, and Karen J. Brunke elected as directors for one-year terms.
CytoDyn settles Amarex lawsuit for $12M cash payment and $14M liability elimination
Amarex to pay CytoDyn $12 million total, with $10 million received upon execution.
CytoDyn appoints Marcum LLP as new independent auditor effective June 28
Marcum LLP engaged as independent registered public accounting firm effective June 28, 2024.
CytoDyn reports unregistered sale of 52.6M units at $0.13/unit, diluting equity by >5%
52.6M units sold in private placement; 10.1M from note conversions, plus 1.5M follow-on units.
CytoDyn dismisses BF Borgers as auditor after SEC permanent bar; replacement search underway
Dismissed BF Borgers on May 6, 2024, following SEC order on May 3 permanently barring the firm.
On May 2, 2025, the Company entered into an agreement with Robert E. Hoffman (“Mr. Hoffman”), under which Mr. Hoffman will serve as the Company’s Chief Financial Officer (“CFO”), effective May 15, 2025 (the “Employment Agreement”).
Max materiality 0.85 · Median 0.70 · Most common event other_material